{"success":true,"data":{"pressRelease":{"id":"50021","rtpr_id":"nACSCy62Wa","ticker":"NKTR","exchange":"NASDAQ","all_tickers":["NKTR"],"title":"Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Investors to Inquire about Securities Investigation","author":"ACCESSWIRE","published_at":"2026-05-31T15:00:06.385Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May\n31, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential\nclaims on behalf of purchasers of Nektar Therapeutics (\"Nektar\" or \"the\nCompany\") (NASDAQ:NKTR). Investors who purchased Nektar securities prior to\nFebruary 26, 2025, and continue to hold to the present, are encouraged to\nobtain additional information and assist the investigation by visiting the\nfirm's site: bgandg.com/NKTR.\n(https://bgandg.com/NKTR/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=NKTR)\n(https://app.accessnewswire.com/imagelibrary/8b0fbc72-54e0-4586-935e-483a354532b8/image.png)\nNektar Investigation Details\n\nThe investigation concerns whether Nektar and certain of its officers and/or\ndirectors have engaged in corporate wrongdoing.\n\nWhat's Next for Nektar Investors?\n\nIf you are aware of any facts relating to this investigation or purchased\nNektar shares, you can assist this investigation by visiting the firm's site:\nbgandg.com/NKTR\n(https://bgandg.com/NKTR/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=NKTR).\nYou can also contact Peretz Bronstein or his client relations manager, Nathan\nMiller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911 (tel:+9175900911)\n\nNo Cost to Nektar Investors\n\nWe, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions\non a contingency fee basis. That means we will ask the court to reimburse us\nfor out-of-pocket expenses and attorneys' fees, usually a percentage of the\ntotal recovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Nektar Securities Investigation?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide.\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.linkedin.com/in/peretz-bronstein-65a1b411), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.linkedin.com/company/bronstein-gewirtz-&-grossman-llc/), X\n(https://x.com/bgandg_law), Facebook (https://www.facebook.com/BGandG/), or\nInstagram (https://www.instagram.com/bg_and_g/).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 (tel:+9175900911) | info@bgandg.com\n\nAttorney advertising.\n\nPrior results do not guarantee similar outcomes.\n\nSOURCE: Bronstein, Gewirtz & Grossman, LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-nektar-therapeutic-1169357)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSCy62Wa","title":"Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Investors to Inquire about Securities Investigation","author":"ACCESSWIRE","ticker":"NKTR","created":"2026-05-31T15:00:06.385Z","tickers":["NKTR"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May\n31, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential\nclaims on behalf of purchasers of Nektar Therapeutics (\"Nektar\" or \"the\nCompany\") (NASDAQ:NKTR). Investors who purchased Nektar securities prior to\nFebruary 26, 2025, and continue to hold to the present, are encouraged to\nobtain additional information and assist the investigation by visiting the\nfirm's site: bgandg.com/NKTR.\n(https://bgandg.com/NKTR/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=NKTR)\n(https://app.accessnewswire.com/imagelibrary/8b0fbc72-54e0-4586-935e-483a354532b8/image.png)\nNektar Investigation Details\n\nThe investigation concerns whether Nektar and certain of its officers and/or\ndirectors have engaged in corporate wrongdoing.\n\nWhat's Next for Nektar Investors?\n\nIf you are aware of any facts relating to this investigation or purchased\nNektar shares, you can assist this investigation by visiting the firm's site:\nbgandg.com/NKTR\n(https://bgandg.com/NKTR/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=NKTR).\nYou can also contact Peretz Bronstein or his client relations manager, Nathan\nMiller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911 (tel:+9175900911)\n\nNo Cost to Nektar Investors\n\nWe, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions\non a contingency fee basis. That means we will ask the court to reimburse us\nfor out-of-pocket expenses and attorneys' fees, usually a percentage of the\ntotal recovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Nektar Securities Investigation?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide.\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.linkedin.com/in/peretz-bronstein-65a1b411), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.linkedin.com/company/bronstein-gewirtz-&-grossman-llc/), X\n(https://x.com/bgandg_law), Facebook (https://www.facebook.com/BGandG/), or\nInstagram (https://www.instagram.com/bg_and_g/).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 (tel:+9175900911) | info@bgandg.com\n\nAttorney advertising.\n\nPrior results do not guarantee similar outcomes.\n\nSOURCE: Bronstein, Gewirtz & Grossman, LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-nektar-therapeutic-1169357)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-05-31T15:00:06.438667827Z","server_sent_at_ms":1780239606438},"received_at":"2026-05-31T15:00:06.489Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-nektar-therapeutic-1169357"},"analysis":{"id":"39452","press_release_id":"50021","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Bronstein, Gewirtz & Grossman, LLC issued a solicitation notice encouraging Nektar Therapeutics investors to inquire about a securities investigation.\n\nThe firm is investigating potential claims on behalf of purchasers of Nektar securities prior to February 26, 2025, who continue to hold shares.\n\nThis is a routine law-firm marketing release soliciting plaintiffs; it contains no new disclosure from Nektar Therapeutics itself.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace","namedEntities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner"},{"name":"Nathan Miller","role":"Client Relations Manager"}],"products":[],"companies":[{"name":"Bronstein, Gewirtz & Grossman, LLC","relationship":"plaintiff law firm"},{"name":"Nektar Therapeutics","ticker":"NKTR"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Bronstein, Gewirtz & Grossman, LLC. No new disclosure from the issuer; no certified class, no settlement. Boilerplate investigation notice."},"tickerRelevance":{"others":[],"primary":"NKTR"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bronstein, Gewirtz & Grossman, LLC issued a solicitation notice encouraging Nektar Therapeutics investors to inquire about a securities investigation.\n\nThe firm is investigating potential claims on behalf of purchasers of Nektar securities prior to February 26, 2025, who continue to hold shares.\n\nThis is a routine law-firm marketing release soliciting plaintiffs; it contains no new disclosure from Nektar Therapeutics itself.","key_figures":{},"named_entities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner"},{"name":"Nathan Miller","role":"Client Relations Manager"}],"products":[],"companies":[{"name":"Bronstein, Gewirtz & Grossman, LLC","relationship":"plaintiff law firm"},{"name":"Nektar Therapeutics","ticker":"NKTR"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-31T15:04:15.704Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":17891,"modelName":"george-droid-qwen-72b"}}